Two Brothers, a Big Biotech Bet and an $8 Billion Payout

PivotalPath research featured in the The Wall Street Journal.

Proud to provide context for a great story this weekend by Peter Rudegeair in the The Wall Street Journal. With biotech investing becoming a dominant strategy for healthcare focused funds, it’s important to understand how individual performance compares to a meaningful peer group benchmark – especially as some funds experience record windfalls.

The PivotalPath Healthcare Index gained 13.3% in 2023, outpacing a 7.6% rise in our Composite Index.
 
Click here to read the full article